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Abstract 24 
Morphogenetic transitions of the opportunistic fungal pathogen Candida albicans are 25 
influenced by temperature changes, with induction of filamentation upon a shift from 30 26 
to 37°C. Hsp90 was identified as a major repressor of an elongated cell shape 27 
morphology at low temperatures, as treatment with specific inhibitors of Hsp90 results in 28 
elongated growth forms at 30°C. Elongated growth resulting from a compromised Hsp90 29 
is considered neither hyphal nor pseudohyphal growth.  It has already been reported that 30 
ascorbic acid (Vitamin C) interferes with the yeast-to-hyphae transition in C. albicans.  In 31 
the present study, we show that ascorbic acid also antagonizes the morphogenetic change 32 
caused by hampered Hsp90 function. Further analysis revealed that Upc2, a 33 
transcriptional regulator of genes involved in ergosterol biosynthesis, and Erg11, the 34 
target of azole antifungals whose expression is in turn regulated by Upc2, are required for 35 
this antagonism. Ergosterol levels correlate with elongated growth, being reduced in cells 36 
treated with the Hsp90 inhibitor Geldanamycin (GdA), and restored by co-treatment with 37 
ascorbic acid.  38 
In addition, we illustrate that Upc2 appears to be required for ascorbic acid-mediated 39 
inhibition of the antifungal activity of fluconazole. These results identify Upc2 as a major 40 
regulator of ascorbic acid-induced effects in C. albicans and suggest an association 41 
between ergosterol content and elongated growth upon Hsp90 compromise. 42 
43 
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Introduction 44 
Candida albicans belongs to the few fungal species that are frequently encountered as 45 
clinical pathogens (1). C. albicans is a frequent commensal of healthy individuals but 46 
when the host immune system is weakened, it can become a deadly pathogen (2). Its 47 
pathogenic nature relies on a multitude of factors, including the ability to grow at 37 °C, 48 
to produce adhesins and hydrolases and to change between different morphological 49 
forms, including yeast cells, hyphae, pseudohyphae, chlamydospores, opaque cells and 50 
the recently described GUT morphology (3-5). It is generally assumed that the yeast form 51 
is crucial for fungal dissemination via the bloodstream throughout the body (6), while 52 
hyphae on the other hand are required for the production of extracellular enzymes and 53 
invasive growth (7).   54 
The yeast-to-hyphae transition of C. albicans can be triggered by environmental cues 55 
such as pH, serum, elevated temperature and CO2 (4, 8). In addition several small 56 
molecules, such as autoregulatory molecules, cell cycle inhibitors and histone deacetylase 57 
inhibitors, are also capable of modulating morphogenetic responses (9, 10). Most 58 
environmental triggers and small molecules function through activation of the cAMP-59 
PKA or MAPK pathways via their downstream transcription factors Efg1 and Cph1, 60 
respectively (4, 11, 12). Over the past few years, several reports appeared that showed 61 
that Geldanamycin (GdA), a benzoquinone ansamycin antibiotic is another small 62 
molecule that strongly affects the cell shape of C. albicans at 30 °C as its addition results 63 
in elongated cells. GdA inhibits the function of Hsp90 by binding to its ADP/ATP 64 
binding pocket (10, 13) indicating that Hsp90 prevents an elongated cell shape of C. 65 
albicans at lower temperatures. This morphogenetic process also involves the Ras1-66 
 4
cAMP-PKA signalling pathway but it seems to do this independent of the downstream 67 
transcription factor Efg1, suggesting the involvement of other transcriptional regulators 68 
(13). Screening of a transcription factor (TF) deletion collection for mutants impaired in 69 
the Hsp90-mediated elongated cell shape phenotype, resulted in the identification of 70 
Hms1 (14).  Two upstream regulators of this TF, the cyclin-dependent kinase Pho85 and 71 
the cyclin Pcl1 are also required for elongated cell shape (14). As Hms1 is not a 72 
component of the cAMP-PKA pathway, the link between Hsp90-dependent elongated 73 
cell shape and the Ras1-PKA signalling pathway remained to be identified. Our aim in 74 
this work was to identify transcription factors that upon overexpression affect the Hsp90-75 
depended elongated cell shape. For this we screened a TF overexpression library and we 76 
found that overexpression of Upc2 prevents the elongated growth phenotype when GdA 77 
is added. The Zn2Cys6 transcriptional regulator Upc2 is important for the regulation of 78 
the ergosterol biosynthetic pathway in response to commonly used antifungals (15). This 79 
transcription factor can act as a repressor or an activator depending on its target and on 80 
the initiating conditions, and exerts its function by binding to sterol response elements 81 
(SREs) (15-17). Gain-of-function mutations in UPC2 have been associated with 82 
resistance to antifungal treatments (18-21), while strains devoid of Upc2 are 83 
hypersusceptible to azole antifungals (22). One of the genes regulated by Upc2 is Erg11, 84 
which is a key enzyme in the biosynthesis of ergosterol and it is the target of the azole 85 
antifungal drugs.  Overexpression of Erg11 has been shown to cause tolerance to these 86 
drugs. 87 
In order to find components linking the GdA-induced elongated growth phenotype and 88 
the block of this phenotype upon overexpression of UPC2, we have tested a number of 89 
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compounds that were shown to mediate morphogenesis in C. albicans. Ascorbic acid 90 
(vitamin C) was previously shown to play a role in morphogenesis as it blocks serum-91 
initiated hyphae formation, a process mediated by adenylate cyclase (23, 24). How 92 
ascorbic acid affects morphogenesis is not clear and we propose that it may function by 93 
modulating the role of Hsp90 in cell shape formation. In this paper, we describe a 94 
previously unreported negative effect of ascorbic acid on the Hsp90-dependent cell 95 
shape. Focusing on the mode of action of ascorbic acid, we provide evidence that it 96 
requires Upc2 and Erg11 to exert its function. We further demonstrate that intracellular 97 
ergosterol levels play a role in the ascorbic acid mediated effect on cell shape. In 98 
addition, we show that Upc2 is also required for the antagonistic effect of ascorbic acid 99 
on fluconazole toxicity. Together, these results show that ascorbic acid inhibits the 100 
Hsp90-mediated cell shape transition via the transcriptional regulator Upc2.  101 
 102 
Materials and methods 103 
 104 
Strains and growth conditions 105 
Strains used in this study are listed in Table 1.  C. albicans strains were grown overnight 106 
in 3 ml of YPD (1 % yeast extract, 2 % bacteriological peptone and 2 % glucose) at 30°C.  107 
Cells were subsequently diluted to OD600=0.2 and cultured for indicated time points at 108 
30°C with the indicated treatment (4 µM or 10 µM Geldanamycin; 2.5 mM ascorbic acid, 109 
L-cysteine, D-cysteine, glutathione or dithiotreitol (DTT), 0.1 µg/ml doxycycline). When 110 
ascorbic acid was added, the medium was buffered to pH 7. All chemicals were 111 
purchased from Sigma-Aldrich. 112 
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Transcription factor overexpression strains were grown in Complete supplement mixture 113 
minus methionine (CSM-Met medium : 0.073 % CSM-Met-Ura, 0.17 % YNB w/o amino 114 
acids and (NH4)2SO4, 0.5 % (NH4)2SO4, pH5.5) supplemented with 0.1 % uridine and the 115 
indicated treatment (10 µM GdA, 2.5 or 10 mM methionine). 116 
 117 
Microscopy 118 
Imaging of the cells was done by differential interference contrast microscopy using the 119 
Zeiss Axioplan 2 microscope. Images were obtained by a Zeiss Axiocam MRc5 camera 120 
using Axiovision software 3.0 (Carl Zeiss, Inc. NY). 121 
 122 
Cell sedimentation assay  123 
The cell-sedimentation rate was quantified using the assay described by Eboigbodin and 124 
Biggs (25) and Fu et al. (26). Cells were grown in YPD liquid medium with (0.1 µg/ml, 125 
for transcriptional repression) or without doxycycline and 2.5 mM of L-cysteine or 126 
ascorbic acid. OD600 was determined at indicated time points of the cells at the upper part 127 
of the glass tube, as sediments settle to the bottom of the glass tube. The formula (ODI -128 
ODt/ODI) x 100 was utilized to calculate the percentage of sedimented cells.  ODI is the 129 
initial OD taken at time zero and ODt is the OD taken at the indicated time point.  130 
 131 
Upc2 overexpression strain: Transcription factor library 132 
The UPC2 overexpression strain used in this study is part of a transcription factor 133 
overexpression library, constructed in our laboratory on the basis of the previously 134 
developed Candida albicans two-hybrid system (27).  Briefly, the nuclear localization 135 
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sequence (NLS) was removed from the one-hybrid plasmid pC2HB resulting in pC1H. 136 
Subsequently, genes encoding known and putative transcription factors were successfully 137 
cloned in fusion with the DNA-binding domain LexA in this plasmid, to create the pC1H-138 
PTF library. The resulting plasmids were integrated in the two-hybrid reporter strain 139 
S2CH3 (27) between XOG1 and HOL1 loci on chromosome 1 after linearization at the 140 
NotI restriction site. Selection was performed on CSM-leu medium. The complete library 141 
consists of ~200 strains, each carrying an ectopically expressed protein, under the control 142 
of an inducible MET3 promoter (Stynen et al., under preparation). The use of the 143 
inducible MET3 promoter allows for a conditional expression, as it is repressed in the 144 
presence of methionine and cysteine (28).  145 
 146 
Ergosterol extraction and quantification 147 
Ergosterol extraction and quantification was performed as reported by Arthington-Skaggs 148 
et al. (29), with minor modifications.  Briefly, cells were grown overnight in 4 ml YPD at 149 
30 °C.  Cells were diluted to OD600 =0.2 and grown in YPD medium supplemented with 150 
10 µM GdA, 2.5 mM ascorbic acid or a combination of both.  After the indicated time 151 
period, 220 ODs of cells at 600 nm [concentration of cells (OD/ml) x volume (ml) = 220 152 
OD] were used in the heptane extraction. The same procedure was used for all 153 
experimental conditions. Cells were harvested by centrifugation at 3.000 rpm for 5 min 154 
and washed once with 10 ml sterile water. Three milliliters of 25 % alcoholic potassium 155 
hydroxide solution (25 g KOH and 35 ml sterile H2O were brought to 100 ml with 100 % 156 
ethanol) was added to each pellet and vortexed for 1 minute. Cell suspensions were 157 
heated in an 85 °C water bath for 1 hour, then allowed to cool down at room temperature. 158 
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Sterols were extracted with a mixture of 1 ml of sterile water and 3 ml of n-heptane 159 
followed by mixing for 3 min.  The organic layer was transferred to a clean glass tube 160 
and stored at -20°C for 24 h. Prior to the spectrophotometrical scan between 230 and 300 161 
nm using a Shimadzu UV-1650PC spectrophotometer, sterol extracts were diluted 162 
fivefold in 100% ethanol.  A dilution of heptane and ethanol was used as the blank. 163 
Ergosterol levels were subsequently calculated as a percentage of the wet weight as 164 
described (29). 165 
 166 
Quantitative real-time PCR 167 
Overnight cultures of C. albicans strains were diluted to an OD600=0.2 and cultures were 168 
grown at 30 °C for the indicated time points in the presence and absence of either 169 
doxycycline (0.1 µg/ml), ascorbic acid (2.5 mM) and GdA (10 µM) before RNA 170 
extraction. RNA was DNase-treated prior to cDNA synthesis with the Promega A3500 171 
reverse transcription kit. Quantitative real-time PCR was performed using the GoScript™ 172 
Reverse Transcription System (Promega) on a StepOne Plus real-time PCR system 173 
(Applied Biosystems). Reactions were performed in triplicate, with oligonucleotides 174 
CaERG11up, CaERG11down; Upc2_fw, Upc2_rv; Hsp90_fw, Hsp90_rv; TEF1a-fw and 175 
TEF1a-rv as the primer pairs (Table 2). The fold regulation was determined using the 176 
∆∆Ct method, using expression of TEF1 to normalize the data. 177 
 178 
Checkerboard assay 179 
A checkerboard assay on 96-well plates was performed, by combining different 180 
concentrations of ascorbic acid and fluconazole and the fractional inhibitory 181 
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concentration index (FICI) was determined. The assay was performed with both the wild 182 
type and the UPC2 deletion mutant to verify whether the effect of ascorbic acid on 183 
fluconazole susceptibility is exerted via Upc2. 184 
The concentrations of ascorbic acid ranged from 0.078 mM to 5 mM for both the wild 185 
type and the UPC2 deletion mutant.  The concentration of fluconazole ranged from 0.004 186 
µg/ml to 2 µg/ml for the UPC2 deletion mutant and 0.125 µg/ml to 64 µg/ml for the wild 187 
type. The FICI was calculated according to the formula FICindex = FICA + FICB = (MICA 188 
comb/MICA alone) + (MICB comb/MICB alone), where MICA alone and MICB alone are the MICs of 189 
ascorbic acid and fluconazole alone and MICA comb and MICB comb are the MICs of 190 
ascorbic acid and fluconazole in combination.  Interactions were referred to as synergistic 191 
when the FICindex value was < 0.5 and antagonistic when the FICindex value was > 4.  192 
FICindex values that were > 0.5 and < 4 indicated no interaction between ascorbic acid and 193 
fluconazole (30). There was no difference in FIC indexes observed between 24 and 48 h. 194 
 195 
Oxidative stress sensitivity assay 196 
The wild type and the two independent UPC2 deletion mutants of the Homann collection 197 
(33) were grown to mid log phase in liquid YPD medium. Cells were diluted to OD600 of 198 
1 and ten-fold serially dilutions were spotted on YPD plates containing the indicated 199 
concentrations of H2O2. Plates were photographed after 24 hours incubation at 37°C.  200 
 201 
Propidium iodide staining 202 
Viability staining was performed by incubating a subset of cells (taken at the indicated 203 
time points of the experiments) for 20 min in the dark with the fluorescent stain 204 
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propidium iodide (PI; 46 mM) (Sigma-Aldrich).  Prior to PI fluorescence analysis 205 
(excitation/emission maxima: 535/617 nm), cells were washed and resuspended in PBS. 206 
 207 
Statistical analysis 208 
Statistical significance was calculated using a student t-test analysis with (P<0.05 = *) 209 
and (P<0.001 = **). All experiments were performed with at least three biological 210 
repeats. 211 
 212 
Results 213 
 214 
Ascorbic acid interferes with the morphogenetic process governed by Hsp90 215 
The transition from C. albicans yeast to hyphae can be induced or repressed by a wide 216 
variety of triggers (31). Partial inhibition of Hsp90, obtained by either addition of GdA, 217 
or by decreased transcription of the corresponding HSP90 gene, results in elongated cells, 218 
which are considered neither hyphae nor pseudohyphae (13). In order to understand the 219 
mechanism by which Hsp90 affects morphogenesis, we have tested a number of 220 
compounds known to inhibit filamentation for interaction with GdA, and determined the 221 
effect of ascorbic acid on the GdA-induced elongated growth. Addition of ascorbic acid, 222 
which was previously reported to interfere with the yeast-to-hyphae transition (24), 223 
resulted in a strong reduction of the GdA-induced elongated cell shape (Figure 1A). 224 
Similar results were obtained using Radicicol, an Hsp90 inhibitor structurally distinct 225 
from GdA (32) (data not shown). Since Hsp90 is an essential chaperone, cell viability 226 
was assessed by propidium iodide (PI), a dye that is excluded from viable cells. As shown 227 
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in Figure 1B, the viability of GdA-treated cells is similar to that of untreated cells, ruling 228 
out possible effects due to elevated cell mortality. 229 
To test whether the observed effect of ascorbic acid was dependent on Hsp90, or the 230 
result of chemical-chemical interference with GdA, similar experiments were conducted 231 
using a strain whose Hsp90 content can be modulated via the use of a tetracycline-232 
repressible promoter (13). As expected, lowering the expression of HSP90 with 233 
doxycycline in this strain resulted in elongated growth (Figure 2A). Cell viability was 234 
also tested here and indicated that cells were alive (Figure 2B). Addition of ascorbic acid 235 
to cells genetically depleted of Hsp90 greatly increased the percentage of yeast cells (75 236 
%), as compared to the control condition without the addition of ascorbic acid (32 %) 237 
(Figure 2C). The effect of ascorbic acid was also determined using a sedimentation assay. 238 
Addition of ascorbic acid to cells in a liquid culture resulted in a slower sedimentation 239 
rate, indicating a higher proportion of yeast cells in these cultures as compared to 240 
ascorbic acid-untreated cells (Figure 2D). Since transcription of HSP90 in the tetO-241 
HSP90 strain is reduced in the presence of doxycycline, the possibility of a chemical 242 
doxycycline-ascorbic acid interaction was ruled out in experiments with wild type control 243 
cells. Here, the concentration of doxycycline used in our experiments was demonstrated 244 
to not interfere with the effect of ascorbic acid on the GdA-dependent elongated cell 245 
shape described above (Supplementary Figure 1A). We also confirmed that doxycycline-246 
mediated repression of Hsp90 was not significantly altered in the presence of ascorbic 247 
acid (Supplementary Figure 1B). Taken together, these results indicate that ascorbic acid 248 
has a negative effect on elongated cell shape formation resulting from lower Hsp90 249 
activity or expression.  250 
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 251 
Upc2 is required for the ascorbic acid-mediated effect.  252 
A transcription factor deletion collection was previously used to characterize the 253 
regulatory system mediating Hsp90-regulated elongated growth (14). In a complementary 254 
approach, we have screened a transcription factor overexpression library to identify TFs 255 
that upon overexpression prevent GdA-induced morphogenesis. The library consists of 256 
~200 strains, each carrying an ectopically expressed TF, under the control of the 257 
inducible MET3 promoter (Stynen et al., under preparation). Methionine only was used to 258 
repress transcription, as cysteine was shown to interfere with elongation even in a wild 259 
type strain due to its antioxidant properties (see discussion and Supplementary Figure 2). 260 
Several transcriptional regulators whose overexpression resulted in blocked or decreased 261 
elongated growth in the presence of GdA were identified (Table 3). We continued with 262 
the strain overexpressing UPC2 (Figure 3A), as it showed the strongest effect, based on 263 
semi-quantitative observations. Expression of UPC2 in inducing conditions was ~4.5-fold 264 
higher than an isogenic control strain carrying an empty plasmid (Figure 3A). As 265 
expected, the characteristic elongated growth form was visible when the MET3 promoter 266 
was repressed by the addition of methionine, confirming that increased dosage of Upc2 is 267 
responsible for the loss of elongation in the presence of inactive Hsp90 (Figure 3B).  268 
To confirm the role of Upc2 in the Hsp90-mediated inhibition of elongated growth forms, 269 
we tested two independent strains in which the endogenous UPC2 genes were deleted 270 
(22, 33), as such strains are expected to be hypersusceptible to GdA. Treatment of the 271 
wild type strain with low concentrations of GdA (4µM) has no effect on morphogenesis 272 
of wild type cells. However, the same concentration was sufficient to induce elongated 273 
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growth in the upc2∆/upc2∆ strains, confirming their hypersusceptibility (strain D-6 is 274 
shown in Figure 4A). In the complemented strain, elongation was impaired (Figure 4A). 275 
Taken together, these observations indicate that Upc2 plays a role in the GdA-associated 276 
elongation process, and confirm the previously observed genetic interaction between 277 
Upc2 and Hsp90 (34).  278 
The obvious question was then whether Upc2 is required for the effect that ascorbic acid 279 
has on the Hsp90-mediated cell elongation. Addition of ascorbic acid to wild type cells 280 
prevents the GdA-induced cell elongation. In the absence of Upc2 (in both independent 281 
deletion strains D-6 and TF077) the GdA-induced cell elongation was not affected 282 
whereas the UPC2-reconstituted strain EC-7 resulted in a similar phenotype as the wild 283 
type strain (Figure 4B).  These results indicate that the effect of ascorbic acid on the 284 
morphological response upon inhibition of Hsp90 is Upc2-dependent.  285 
 286 
Hsp90 inhibition or depletion results in reduced intracellular ergosterol levels 287 
To determine the mechanism by which ascorbic acid and Upc2 affect elongated cell 288 
growth, we tested the role of genes whose expression are regulated by Upc2, such as the 289 
drug efflux pumps CDR1 and MDR1 (17, 35). First, we hypothesized that ascorbic acid 290 
could increase the efflux of GdA, which was reported to be a substrate of the human ABC 291 
(ATP-binding cassette) transporter efflux pump, Mdr1 (36, 37). If this hypothesis were 292 
valid in C. albicans, one would expect mutants lacking Cdr1, a fungal ABC multidrug 293 
transporter (38) to elongate in the presence of both GdA and ascorbic acid. In addition, 294 
one would expect a strain devoid of this efflux pump to be hypersusceptible to GdA.  295 
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However, neither hypersusceptibility to GdA nor impairment of the morphogenetic effect 296 
of ascorbic acid was observed for the cdr1∆/cdr1∆ mutant (data not shown). 297 
We also investigated Mdr1, a member of the multidrug resistance (MDR1) major 298 
facilitator family. Strains overexpressing MDR1 (39) or deleted for MDR1 were not 299 
affected in the ascorbic acid-mediated effect and were not hypersusceptible to GdA (data 300 
not shown). Together, these results rule out the hypothesis that an ascorbic acid-mediated 301 
increased efflux of GdA is causative for the ascorbic acid-mediated phenotype. 302 
Apart from CDR1 and MDR1, expression of ERG11, a key gene in the ergosterol 303 
biosynthesis pathway, is also under the control of Upc2 (15, 22, 40). We therefore 304 
reasoned that levels of Erg11 might play an instrumental role in the morphogenetic 305 
transition regulated by Hsp90. The role of Erg11 on the ascorbic acid induced inhibition 306 
was investigated using an engineered strain in which the only ERG11 allele is under the 307 
control of a tetracycline-repressible promoter (41). Cells, in which the transcription of 308 
ERG11 was repressed by the addition of doxycyclin, but that were still viable 309 
(Supplementary Figure 3), were tested for GdA-induced elongation in the presence of 310 
ascorbic acid. As shown in Figure 5A (compare a, c, g and h), Erg11 expression is 311 
required for the ascorbic acid induced inhibition of cell elongation upon GdA treatment. 312 
We also tested an ERG11 overexpression strain (~3.5-fold higher expression compared to 313 
the control strain) (42) but, as shown in Figure 5B, such increased dosage of ERG11 was 314 
not able to suppress the elongated phenotype upon Hsp90 inhibition, demonstrating that 315 
an increased dosage of Erg11 is not sufficient to block GdA-induced elongation. We also 316 
investigated whether ascorbic acid induces ERG11 expression in the presence and 317 
absence of Hsp90 inhibitors. In the wild type strain, there is a significant drop in ERG11 318 
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expression upon GdA treatment, while simultaneous addition of ascorbic acid upon this 319 
treatment leads to an increased transcription of ERG11 (Figure 5C). This increase is 320 
absent in an upc2∆/upc2∆ mutant, suggesting a role for Upc2 as an important regulator. 321 
Erg11’s eminent role in the regulation of sterol biosynthesis (15, 22, 43) and ascorbic 322 
acid-mediated effects on the Hsp90 morphogenetic circuitry (Figure 1A and 2A), 323 
suggests a possible relationship between ergosterol content and ascorbic acid induced 324 
inhibition of cell elongation in the presence of GdA. To verify the impact of an impaired 325 
Hsp90 function on ergosterol levels, we determined ergosterol levels in wild type and 326 
upc2∆/upc2∆ strains upon treatment with GdA (10 µM) and/or ascorbic acid (2.5 mM). 327 
As shown in Figure 6A, a significant decrease in ergosterol levels can be observed after 328 
addition of GdA to the wild type strain (P < 0.05) and the upc2∆/upc2∆ mutant (P < 329 
0.001) compared to the corresponding untreated control strains. Whereas ergosterol levels 330 
are restored when ascorbic acid (2.5 mM) is added together with GdA to the wild type 331 
strain, addition of both compounds to upc2∆/upc2∆ cells failed to show a similar 332 
restoration. The difference in ergosterol levels compared to the untreated upc2∆/upc2∆ 333 
mutant remained significant (P < 0.05). As can be seen, there is also a detectable 334 
decrease in ergosterol levels when ascorbic acid alone is administered, but this reduction 335 
is not significant (P > 0.05). These results point to a correlation between ergosterol levels 336 
and Hsp90-governed elongated growth. To rule that reduced ergosterol levels were the 337 
result of oxidative stress caused by the absence of Upc2 as was previously claimed (44), 338 
we tested the two independent upc2 mutant strains from the Homann collection (33) that 339 
we used throughout our paper, for their susceptibility towards oxidative stress. 340 
Supplementary figure 4 shows that the tolerance to H2O2 of the mutants is absolutely 341 
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comparable to that of the corresponding isogenic wild type strain, thus ruling out the 342 
hypothesis that deletion of UPC2 could lower the anti oxidative stress potential of the 343 
cells. Different response of other upc2 mutants to oxidative stress may have different 344 
causes, such as a different genetic background (44). 345 
Results obtained with pharmacological inhibition of Hsp90 were confirmed using genetic 346 
depletion of Hsp90. The tetO-HSP90/hsp90∆ strain was grown in the presence and 347 
absence of doxycycline and ergosterol levels were determined. As shown in Figure 6B, 348 
depletion of Hsp90 results in a significant decrease in ergosterol levels (P < 0.001). 349 
Similar to the pharmacological inhibition, addition of ascorbic acid results in restoration 350 
of ergosterol levels, with higher ergosterol in the presence of higher ascorbic acid. To 351 
rule out a more indirect effect of ascorbic acid on ergosterol levels via its antioxidant 352 
effect we have analyzed ROS production by way of rhodamine fluorescence in the wild 353 
type strain and in the Tet0-HSP90/hsp90∆ strain in the presence or absence of 354 
doxycycline, and with or without ascorbic acid. Fluorescence of doxycycline-, as well as 355 
of doxycycline and ascorbic acid-treated cells was comparable to that of untreated cells. 356 
H2O2-treated cells were used as the positive control (data not shown).  357 
These results suggest that decreased ergosterol levels caused by Hsp90 inhibition (Figure 358 
6A and 6B) promote elongated growth. However, Figure 5A (panel d) shows that a 359 
reduction of ergosterol levels (by downregulating ERG11 expression) was not sufficient 360 
to induce elongation, since elongated growth forms still required Hsp90 inhibition.  361 
To our knowledge, this is the first time that a clear correlation between 362 
impaired/decreased Hsp90 expression, and ergosterol levels has been observed. 363 
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Moreover, addition of ascorbic acid restores ergosterol levels to wild type levels and this 364 
is clearer upon pharmacological inhibition, compared to genetic depletion of Hsp90.  365 
 366 
Upc2 is required for other ascorbic acid-mediated effects 367 
It has been reported in previous studies that ascorbic acid reduces the antifungal effect of 368 
fluconazole, possibly via its antioxidant properties (45). The authors suggested that the 369 
antioxidant properties of ascorbic acid counteract fluconazole-induced reactive oxygen 370 
species, resulting in a similar effect obtained with other antioxidants such as glutathione 371 
(45). In order to establish a general role for Upc2 in orchestrating ascorbic acid-mediated 372 
phenomena, we verified a possible relationship between ascorbic acid and fluconazole in 373 
a upc2∆/upc2∆ strain by means of checkerboard assays, two-dimensional tests designed 374 
to measure drug-drug interactions. Fluconazole and ascorbic acid display antagonistic 375 
activity, as determined via the calculation of the fractional inhibitory concentration  (FIC) 376 
index (FIC index 33, Table 4). This kind of interaction is no longer detectable when the 377 
checkerboard is performed using cells of the upc2∆/upc2∆ strain (FIC index 0.75, Table 378 
4). Thus, the combination of ascorbic acid with fluconazole no longer displayed 379 
antagonistic activity in cells lacking the Upc2 transcription factor.  380 
 381 
Discussion 382 
 383 
Decreased dosage of Hsp90, as well as its pharmacologic depletion, results in a 384 
morphology change of C. albicans at low temperature from yeast to elongated cells (13). 385 
The molecular mechanism of this morphogenetic transition has been studied extensively 386 
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over the last few years (46, 47). We contribute to this characterisation by showing that 387 
reduced levels of ergosterol result from GdA-mediated impairment of Hsp90, and that 388 
these changes correlate with elongated growth. The effect of GdA can be suppressed by 389 
addition of ascorbic acid, as this again increased levels of ergosterol to normal and 390 
resulted in cell growth in the yeast form. Ascorbic acid suppression did not depend on its 391 
anti oxidant activity, but depends on the transcriptional regulator Upc2, as in a 392 
upc2∆/upc2∆ mutant ascorbic acid cannot restore ergosterol levels to normal upon GdA 393 
treatment. In summary, ascorbic acid can block the GdA-dependent elongated growth by 394 
restoring normal ergosterol levels in a Upc2-dependent fashion.  395 
In the course of our work we found that several antioxidants interfered with the activity 396 
of GdA. Apart from its known inhibition of Hsp90, GdA is also involved in the 397 
generation of superoxide radicals, which is attributed to the presence of its quinone group 398 
(48). The presence of molecules with antioxidant properties alleviates the detrimental 399 
effects of oxidative stress imposed by free radicals. A variety of molecules such as 400 
reduced glutathione (GSH) and its derivatives, cysteine, dithiothreitol and ascorbic acid 401 
are able to fulfil these protective requirements (49). It could be possible that the 402 
superoxide radicals produced in the presence of GdA could affect the elongated cell 403 
shape formation and addition of ascorbic acid would then block this through its anti 404 
oxidant activities. This would fit with data obtained by Patterson et al. (50) who showed 405 
that H2O2-mediated activation of Cap1 was a prerequisite for yeast to hyphae transition.  406 
However, the fact that the antagonistic effect of ascorbic acid on morphology is observed 407 
on cells genetically depleted of Hsp90 as well as on cells whose Hsp90 is inhibited by 408 
GdA, suggests that ascorbic acid acts directly or indirectly on Hsp90 or Hsp90-mediated 409 
 19
processes. Other authors have reported an influence of ascorbic acid or its analogues on 410 
morphogenetic transitions in C. albicans (23, 24, 51). Nasution and colleagues (23) 411 
reported that addition of ascorbic acid not only lowered the intracellular concentration of 412 
reactive oxygen species, but also inhibited H2O2 and serum-initiated hyphal 413 
differentiation. Ojha and co-workers (24) similarly demonstrated inhibition of serum-414 
induced hyphal formation by ascorbic acid and suggested a mode of action by 415 
interruption of the hyphal formation signal of C. albicans.  416 
During the TF overexpression screening, we observed that cysteine directly affected the 417 
activity of GdA as no elongated growth could be observed in the wild type strain. This 418 
could be explained by earlier reports describing that thiol-containing antioxidants (such 419 
as cysteine) could physically interact with Hsp90 inhibitors, such as GdA and Radicicol, 420 
and render them inactive as a consequence of the thiol-mediated interaction (52-57). This 421 
means that one has to be careful when using the MET3-promoter in combination with 422 
GdA or Radicicol as in this case cysteine, that is used to repress the promoter, will affect 423 
the activity of GdA and Radicicol. This is the reason why in our experiments we used 424 
only methionine to repress the MET3 promoter.  425 
 426 
One of the TFs that inhibited the GdA-induced morphogenesis was Upc2, a Zn2Cys6 427 
transcription factor, a key regulator of drug efflux pump expression and ergosterol 428 
biosynthesis (15, 35). Here we show that Upc2 is required for the ascorbic acid inhibition 429 
of cell elongation upon compromised Hsp90 function. Previously it was already shown 430 
that Upc2 is a key regulator of the ascorbic acid-mediated effect on fluconazole, as it 431 
decreases the antifungal effect of fluconazole, so displaying a protective role in fungi 432 
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(45). Together, these data show that Upc2 plays a central role as the transcriptional 433 
regulator in ascorbic acid-associated phenomena. Ascorbic acid is very important for 434 
human life because of its antioxidant properties, protecting cells from oxidative stress 435 
(58). The use of ascorbic acid is even clinically relevant for the treatment of a variety of 436 
diseases, such as respiratory tract infections (59, 60). 437 
One of the genes that is regulated by Upc2 is ERG11, a gene involved in ergosterol 438 
biosynthesis and the molecular target of the azole antifungals (15, 22, 43, 61, 62). 439 
Previous work demonstrated that lower ergosterol levels, caused by ergosterol 440 
biosynthesis inhibitors such as azoles, have an inhibitory effect on hyphae formation (63, 441 
64). However, elongated growth forms resulting from impaired Hsp90 function are not 442 
considered true hyphae (14, 65, 66). Consistent with the relationship between ergosterol 443 
depletion and C. albicans morphogenesis mentioned by Victoria et al. (67), we report a 444 
correlation between ergosterol content and elongated growth caused by impairment of 445 
Hsp90 function. The morphogenetic switch to elongated growth forms by either 446 
pharmacological inhibition or genetic depletion is accompanied with a significant 447 
decrease in ergosterol content. One could question whether this drop in ergosterol is 448 
really the cause or rather a consequence of the morphogenetic transition upon Hsp90 449 
inhibition. The formation of elongated growth structures upon low ergosterol levels could 450 
be interpreted as a cellular stress response caused by the disruption of the sterol 451 
homeostasis. However, this seems unlikely, since our results argue against an elongation-452 
inducing role for low ergosterol levels. First, we demonstrated that reduced levels of 453 
Erg11 are not sufficient to promote elongation (Figure 5A). In addition, it was found that 454 
increasing concentrations of ascorbic acid reduced ergosterol content without initiating 455 
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elongated growth (Figure 6A and B). These latter data are consistent with previous 456 
observations by Singh et al. (68), who reported low ergosterol levels in C. albicans cells 457 
when they were grown in the presence of ascorbic acid.  458 
On the other hand, the increase of ergosterol to wild type levels in the presence of GdA 459 
upon addition of ascorbic acid is absent in a upc2∆/upc2∆ mutant suggesting the 460 
importance of Upc2 as a transcriptional regulator of Erg11 to overcome the drop in 461 
ergosterol levels caused by impaired Hsp90 (Figure 6A). As already mentioned, we show 462 
that an increased dosage of ERG11 alone was not sufficient to overcome the induction of 463 
elongated growth upon pharmacological inhibition of Hsp90. This could indicate that 464 
ergosterol biosynthesis is not the most important Upc2-mediated effect in response to 465 
ascorbic acid or that the expression other ERG genes could be regulated by Upc2. We are 466 
currently identifying other Upc2-regulated genes by performing ChIP-Seq and RNA-seq 467 
analysis. We cannot exclude a possible connection with the previously established 468 
pathways in the Hsp90-dependent morphogenetic circuitry, such as the cAMP-PKA and 469 
cell cycle pathways or the Pho85-Pcl1-Hms1 module (13, 14, 46, 65, 69) or a novel, yet-470 
to-be-determined pathway. Ascorbic acid or Upc2 may be required for the modulation of 471 
an inhibitor of these Hsp90 signalling modules. 472 
 473 
In conclusion, our study elucidates the molecular circuitry through which ascorbic acid 474 
influences the Hsp90-dependent C. albicans morphogenesis, involving the transcriptional 475 
regulator Upc2. We find that ascorbic acid can block the GdA-dependent elongated 476 
growth by restoring normal ergosterol levels in a Upc2-dependent fashion. We suggest 477 
that influencing ergosterol biosynthesis via Erg11 is not the primary site of action of 478 
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Upc2-mediated effects in response to ascorbic acid, as overexpression of ERG11 did not 479 
block elongation upon GdA-treatment. Further research is required to further explore the 480 
interesting relationship between Hsp90, Upc2, Erg11 and the morphogenetic machinery. 481 
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Figure legends 718 
 719 
Figure 1: Ascorbic acid abrogates GdA-induced elongated growth  720 
A) Inhibiting effect of ascorbic acid on elongated growth induced by 10 µM GdA. Wild 721 
type SC5314 cells were grown at 30 °C in liquid rich medium containing GdA (10 µM) 722 
with 2.5 mM ascorbic acid. Pictures were taken after 8 h of growth. B) GdA-mediated 723 
pharmacological inhibition of Hsp90 for extended periods of times is not lethal. 724 
Propidium Iodide stained heat-killed wild type cells (15 min at 80 °C) are clearly 725 
illustrating a complete lethal phenotype as indicated by the staining (which is excluded 726 
from viable cells), while the GdA-treated cells closely resemble the untreated wild type 727 
cells. Pictures were taken after 24 h. 728 
 729 
Figure 2: Ascorbic acid influences phenotypes caused by Hsp90 genetic depletion 730 
A) Ascorbic acid (2.5 mM) counteracts elongated growth upon genetic depletion of 731 
Hsp90 (0.1 µg/ml Dox). Pictures were taken after 24 h. B) Genetic depletion of Hsp90 for 732 
extended of times in the periods of times in the presence of 0.1 µg/ml doxycycline is not 733 
completely lethal. Propidium iodide stained heat killed wild type cells (15 min at 80 °C) 734 
are clearly illustrating a complete lethal phenotype as indicated by the staining, while the 735 
cells genetically depleted of Hsp90 closely resemble the untreated wild type cells. 736 
Pictures were taken at 24 h. C) The percentage of yeast cells grown for 24 h in the 737 
presence of ascorbic acid was significantly (**p < 0.001) higher compared to the 738 
untreated condition D) The sedimentation rate was monitored of cultures of a Candida 739 
strain in which the remaining Hsp90 was under control of a tetracycline-repressible 740 
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promoter in liquid YPD rich medium supplemented with 0.1 µg/ml Dox (), 0.1 µg/ml 741 
Dox + 2.5 mM L-Cysteine (), 0.1 µg/ml Dox + 2.5 mM ascorbic acid () and 0.1 742 
µg/ml Dox + 2.5 mM Glutathione (). The graphs were plotted by percentage of cells 743 
sedimented against time. 744 
 745 
Figure 3: Overexpression of UPC2 represses GdA-induced elongated growth 746 
A) Quantitative real-time PCR of UPC2 expression under the control of the inducible 747 
MET3 promoter, in the UPC2 overexpression strain and the control strain carrying an 748 
identical construct with the exception of the transcription factor. Promoter repressing 749 
conditions in the presence of 10 mM methionine are represented in white, while the black 750 
bars represent inducing conditions. The graph shows mean values with standard 751 
deviations from two independent experiments. B) The inducible MET3 promoter allows 752 
regulated expression. Overexpression of UPC2 in the presence of GdA (10 µM) blocks 753 
the rise of the characteristic elongated growth form. This yeast form is reversed to the 754 
elongated structures under promoter repressing conditions (represented by addition of 10 755 
mM methionine). The control strain carrying an identical expression construct except the 756 
transcriptional regulator, displays a filamentous growth form in both promoter repressing 757 
and inducing conditions. Pictures were taken after 8 h of growth at 30 °C in CSM-met 758 
medium. 759 
 760 
Figure 4: The UPC2 deletion strain is hypersusceptible for GdA and impairs 761 
ascorbic acid associated blockage of the elongated cell shape 762 
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A. The UPC2 deletion strain is hypersusceptible to GdA. The upc2∆/upc2∆ (D-6) strain 763 
was tested for its hypersusceptibility to GdA by treating them with 4 µM of GdA, a 764 
concentration that is unable to induce elongated growth in the corresponding wild type. 765 
The UPC2 re-integrant strain (EC-7) displays a similar phenotype as the wild type.  766 
Pictures were taken after 8 h of growth at 30 °C in YPD medium. B. Deletion of UPC2 767 
impairs ascorbic acid associated blockage of the elongated cell shape. Deletion strains 768 
were grown at 30 °C in YPD rich medium supplemented with either 10 µM GdA, 2.5 769 
mM L-ascorbic acid or a combination of both. While ascorbic acid blocks the GdA-770 
induced filamentation of the wild-type strain, it is unable to do so in the upc2∆/upc2∆ 771 
mutants D-6 and TF077, while the reconstitution of UPC2 restores the yeast growth 772 
response. Pictures were taken after 8 h. 773 
 774 
Figure 5: ERG11 is required for the ascorbic acid-mediated effect 775 
 776 
A) A tetO-ERG11/erg11∆ was grown at 30 °C in YPD rich medium supplemented with 777 
either 10 µM GdA, 2.5 mM L-ascorbic acid, 0.1 µg/ml doxycycline or a combination of 778 
these substances. While ascorbic acid blocks elongation upon GdA-treatment of the tetO-779 
ERG11/erg11∆in the absence of doxycycline, compromising ERG11 expression is able to 780 
overcome this ascorbic acid associated blockage. Pictures were taken after 8 h. B) 781 
Overexpression of ERG11 is not sufficient to block elongated growth caused by Hsp90 782 
inhibition. C. albicans strains AFA60 (control) and AFA59b (ACT1p-CaERG11) were 783 
grown at 30 °C in YPD rich medium supplemented with 10µM GdA. GdA-induced 784 
elongation of both the control and the ACT1p-CaERG11 strain shows that an increased 785 
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dosage of Erg11 cannot suppress elongation. Pictures were taken after 8 h. C) There is a 786 
significant drop (*p < 0.05) in ERG11 expression upon GdA treatment in the wild type, 787 
while simultaneous addition of ascorbic acid upon this treatment leads to an increase.  788 
Interestingly, this latter observation is absent in the upc2∆/upc2∆ mutant, suggesting a 789 
role for Upc2.  Data are means of + standard deviations of triplicate experiments.  790 
 791 
Figure 6: Hsp90 inhibition or depletion result in reduced intracellular ergosterol 792 
levels 793 
A) Ergosterol measurements in the wild type and upc2∆/upc2∆ mutant show a significant 794 
decrease in ergosterol content after pharmacological inhibition of Hsp90 in comparison 795 
with the representative untreated control (*p < 0.05; **p < 0.001).  Addition of ascorbic 796 
acid under these conditions was reflected by an increase of ergosterol content only in the 797 
wild type.  Results are means of at least three independent measurements. Legend: Black: 798 
untreated; Dark grey: 2.5 mM ascorbic acid; Light grey: 10 µM GdA; White: 10 µM 799 
GdA + 2.5 mM ascorbic acid. Data are means of + standard deviations of triplicate 800 
experiments.  801 
B) Ergosterol measurements in the tetO- HSP90/hsp90∆ strain show a similar significant 802 
decrease in ergosterol content in the presence of doxycycline (0.1 µg/ml) compared to the 803 
untreated control (*p < 0.05; **p < 0.001).  This drop in ergosterol levels has great 804 
similarities with pharmacological inhibition by GdA. Addition of ascorbic acid is 805 
reflected by an increase in ergosterol content in the presence of doxycycline, while there 806 
is a general decrease noticeable in its absence. Data are means of + standard deviations of 807 
triplicate experiments.  808 
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Tables 809 
Table 1 : Strains used in this study 810 
 811 
Strain Description Genotype Source 
SC5314  Wild type  (70) 
CAI4  ura3∆::imm434/ura3∆::imm434 
iro1∆/iro1∆::imm343 
(71) 
AFA60a CAI4 transformed with URA3 
vector 
ura3∆::imm434/ura3∆::imm434 
iro1∆/iro1∆::imm343 RPS10::CIp10 
(42) 
AFA59b CAI4 carrying extra copy of 
CaERG11 under control of 
ACT1 promoter 
ura3∆::imm434/ura3∆::imm434 
iro1∆/iro1∆::imm343 
RPS10::pAFC89b  
(42) 
DSY448 cdr1∆/cdr1∆mutant ura3∆::imm434/ura3∆::imm434 
iro1∆/iro1∆::imm343 cdr1∆::hisG-
URA3-hisG/cdr1∆::hisG 
(72) 
DSY465 mdr1∆/mdr1∆mutant ura3∆::imm434/ura3∆::imm434 
iro1∆/iro1∆::imm343 ben∆::hisG-
URA3-hisG/ben∆::hisG 
(72) 
CMDR1E2
A and -B 
CAI4 carrying CaMDR1 under 
control of ADH1 promoter 
ura3∆::imm434/ura3∆::imm434 
iro1∆/iro1∆::imm343 
ADH1/adh1::PADH1-MDR1-URA3 
(39) 
SN152 Background strain TF wild type 
and TF077 
arg4∆/arg4∆ leu2∆ /leu2∆ 
his1∆/his1∆ URA3/ura3∆::imm434 
IRO1/iro1∆::imm343 
(73) 
TF wild 
type 
Control wild type strain (paired 
“wild type” TF077)  
arg4∆ /arg4∆ leu2∆ /LEU2 
his1∆/HIS1 URA3/ura3∆::imm434 
IRO1/iro1∆::imm343 
(33) 
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TF077  upc2∆/upc2∆mutant As SN152, but 
upc2∆::HIS1/upc2∆::LEU2  
(33) 
BWP17 
(TW14901) 
Background strain D-6 and EC-
7 
ura3∆::imm434/ura3∆::imm434 
iro1/iro1∆::imm434 
his1∆::hisG/his1∆::hisG 
arg4∆/arg4∆ 
(22) 
D-6 
(TW14903) 
upc2∆/upc2∆mutant As BWP17 but 
upc2∆::URA3/upc2∆::ARG4 
(22) 
EC-7 
(TW14904) 
Reconstituted strain As D-6 but 
upc2∆::URA3/upc2∆::UPC2-HIS1 
(22) 
pTET-
ERG11  
CAI4 with doxycycline-
repressible ERG11 as the only 
ERG11 allele 
As CAI4, but    
tetO-ERG11/erg11∆  
(41) 
CaLC1411 
(CaLC436) 
Strain with doxycycline-
repressible HSP90 as the only 
HSP90 allele 
arg4∆/arg4∆his1∆/his1∆URA3/ura3
∆::imm434 IRO1/iro1∆::imm434  
HIS1/his1∆::TAR-FRT 
hsp90∆::CdHIS1/his1∆::TAR-FRT 
(74) 
SC2H3  As SN152, but 5xLexAOp-
ADH1b/HIS1 5xLexAOp-
ADH1b/lacZ 
(27) 
OX Control Strain carrying empty vector 
under MET3 promoter 
As SC2H3, but MET3pro:lexA Stynen et 
al., under 
preparation 
Upc2 OX Strain carrying extra copy of 
UPC2 under MET3 promoter 
As SC2H3, but  
MET3pro:lexA:UPC2 
Stynen et 
al., under 
preparation 
Gcn4 OX Strain carrying extra copy of As SC2H3, but  Stynen et 
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GCN4 under MET3 promoter MET3pro:lexA:GCN4 al., under 
preparation 
Cap1 OX Strain carrying extra copy of 
CAP1 under MET3 promoter 
As SC2H3, but  
MET3pro:lexA:CAP1 
Stynen et 
al., under 
preparation 
Dot6 OX Strain carrying extra copy of 
DOT6 under MET3 promoter 
As SC2H3, but  
MET3pro:lexA:DOT6 
Stynen et 
al., under 
preparation 
Rtg3 OX Strain carrying extra copy of 
RTG3 under MET3 promoter 
As SC2H3, but  
MET3pro:lexA:RTG3 
Stynen et 
al., under 
preparation 
 812 
 813 
 814 
Table 2: Primers used in this study 815 
 816 
Primer Description Source 
CaERG11
up 
TTACCTCATTATTGGAGACGTGATG (42) 
CaERG11
down 
CACGTTCTCTTCTCAGTTTAATTTCTTTC (42) 
TEF1a_fw CCACTGAAGTCAAGTCCGTTGA (42) 
TEF1a-rv CACCTTCAGCCAATTGTTCGT (42) 
UPC2_fw GGATGCTCGACATGCAAAAAG This study 
UPC2_rv TGCCACATACAGGTCTCTGTTCA This study 
HSP90_fw CCATCTGATATCACTCAAGATG This study 
HSP90_rv AGTGATAAACACTCTACGGACG This study 
 817 
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 818 
Table 3: Transcription factors that upon overexpression block the GdA-induced elongated growth.  819 
Upc2  Zn2-Cys6 transcriptional regulator of ergosterol biosynthetic genes and sterol uptake 
Cap1  AP-1 family bZIP transcription factor involved in drug resistance and oxidative stress regulation 
Dot6 
 
Uncharacterized ORF, protein with a predicted role in telomeric gene silencing and 
filamentation 
Rtg3  Uncharacterized ORF, putative transcription factor with bZIP DNA-binding motif 
Gcn4  bZIP transcription factor involved in amino acid control response 
 820 
 821 
Table 4: The antagonistic effect of ascorbic acid on fluconazole is not present in a upc2∆/upc2∆ 822 
mutant. MICFLC and MICAA are MICs of fluconazole and ascorbic alone, while MICFLC/AA and MICAA/FLC 823 
are MICs of ascorbic acid and fluconazole in combination.  Interpretation of the FIC index was performed 824 
as previously described (30). 825 
Strain MIC FLC MIC FLC/AA MIC AA MIC AA/FLC FIC index 
Wild type 2 µg/ml >64 µg/ml 
1761.2 µg/ml 
(10 mM) 
1761.2 µg/ml 
(10 mM) 
33 
      
upc2∆/upc2∆ 0.25 µg/ml 0.125 µg/ml 
1761.2 µg/ml 
(10 mM) 
440.3 µg/ml 
(2.5 mM) 
0.75 
 826 
 827 
 828 






